Clobetasol ophthalmic nanoemulsion reduces anterior chamber cells and pain after cataract surgery
Clobetasol drops reduce eye inflammation and pain after cataract surgery
In this phase 3 RCT of 426 patients with post-cataract surgery inflammation, clobetasol propionate ophthalmic nanoemulsion 0.05% four times …
A Phase 3 trial found clobetasol drops significantly reduced eye inflammation and pain compared to placebo in patients after cataract surger…
Secondary analysis of Phase 3 trials shows lebrikizumab improves absolute EASI response in moderate-to-severe atopic dermatitis
New analysis shows lebrikizumab helps clear skin faster than placebo for atopic dermatitis
This secondary analysis of two Phase 3 trials evaluated lebrikizumab 250 mg Q2W versus placebo in adults and adolescents with moderate-to-se…
A look at two major trials found lebrikizumab led to significantly better skin clearing than placebo in adults and adolescents with moderate…
Tucidinostat plus R-CHOP improves outcomes in MYC/BCL2 double-expressor DLBCL
New drug tucidinostat improves outcomes for high-risk lymphoma patients
A phase 3 trial found adding oral tucidinostat to R-CHOP significantly improved event-free survival and complete response rates in patients …
A large trial shows adding tucidinostat to standard chemo lowers disease risk and improves survival for patients with aggressive lymphoma.
Ursodeoxycholic acid reduces ALT and fibrosis in chronic liver disease patients
UDCA Improves Liver Enzymes and Fibrosis in Chronic Liver Disease
This phase IV RCT in 262 patients with chronic liver disease and elevated ALT found that ursodeoxycholic acid 100 mg three times daily for 8…
A phase IV trial found that ursodeoxycholic acid (UDCA) significantly reduced ALT levels and improved fibrosis scores in patients with chron…
Olezarsen showed no significant difference versus placebo in noncalcified plaque volume change over 12 months in adults with moderate hypertriglyceridemia
New trial shows olezarsen did not reduce plaque volume compared to placebo in adults with high triglycerides
This randomized, placebo-controlled trial enrolled 468 adults with moderate hypertriglyceridemia and followed them for 12 months. The primar…
A study of 468 adults found that taking olezarsen did not lower plaque volume better than taking a dummy pill. Safety was also similar betwe…
Post-hoc safety analysis of intramuscular adintrevimab for COVID-19 prophylaxis reports tolerability data
New Shot Feels Like Placebo But Fights COVID Better
This post-hoc safety analysis of a Phase 2/3 randomized controlled trial evaluated intramuscular adintrevimab for COVID-19 pre- and post-exp…
• Experimental antibody causes almost no side effects • Helps people skipping vaccines due to safety fears • Still in testing, not available
Vunakizumab improves ASAS20 response in active radiographic axial spondyloarthritis at 16 weeks
New Drug Offers Hope for Ankylosing Spondylitis Patients
This randomized, double-blind, placebo-controlled phase 2 to 3 trial included 548 adults with active r-axSpA in China. At week 16, the vunak…
If you live with the daily stiffness and pain of ankylosing spondylitis, a new treatment option may be on the horizon that works better than…
MUSKARDIA shows protective trend in stable CAD with reduced eGFR
This Heart Pill from Traditional Medicine Shows Surprising Kidney Protection
A subgroup analysis of a phase IV trial found MUSKARDIA may protect against cardiovascular events in stable CAD patients with reduced kidney…
A traditional Chinese medicine pill already used for heart disease may also shield the kidneys, offering new hope for millions with both con…
Semaglutide reduces insulin dose in adults with type 1 diabetes and obesity
Semaglutide Cuts Insulin Needs By Half In Type 1 Diabetes
A post hoc analysis of an RCT found that semaglutide 1 mg/week significantly reduced total daily insulin dose by 22.6% over 26 weeks in adul…
Semaglutide reduces insulin needs quickly in type 1 diabetes patients, offering a new hope for better blood sugar control and weight managem…
Semaglutide improves physical quality of life in schizophrenia with prediabetes
Semaglutide improves physical quality of life in adults with schizophrenia and obesity
This secondary analysis of a randomized trial in 154 adults with schizophrenia, prediabetes, and overweight or obesity found that once-weekl…
A secondary analysis of a trial found that once-weekly semaglutide improved physical quality of life in adults with schizophrenia and obesit…
Chiglitazar reduces liver fat in MASLD patients with hypertriglyceridemia and insulin resistance
Two doses of chiglitazar cut liver fat far more than a placebo in 18 weeks
In a phase II randomized, double-blind, placebo-controlled trial, 104 patients with MASLD, hypertriglyceridemia, and insulin resistance rece…
Patients with fatty liver disease and high triglycerides saw liver fat drop significantly with chiglitazar compared to placebo after 18 week…
Adjunctive JNJ-42165279 fails to improve depression in SSRI/SNRI inadequate responders
Early trial finds new drug did not help depression in patients already on antidepressants
This phase 2a double-blind RCT tested adjunctive JNJ-42165279 25 mg daily versus placebo in 153 adults with major depressive disorder with a…
A small early study found a new drug did not improve depression symptoms for patients already taking standard antidepressants.